Switch theme
Sign up to access all valuation multiples
Shanghai RAAS Blood Products Co Ltd is a blood products manufacturer in China that has a high comprehensive utilization of plasma raw materials and different specifications. It is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. The main products are human albumin, intravenous human immunoglobulin, coagulation factor products, etc.
1988
272
LTM Revenue $1.2B
LTM EBITDA $421M
$5.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shanghai RAAS has a last 12-month revenue of $1.2B and a last 12-month EBITDA of $421M.
In the most recent fiscal year, Shanghai RAAS achieved revenue of $1.1B and an EBITDA of $326M.
Shanghai RAAS expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shanghai RAAS valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.2B | XXX | XXX | XXX |
| Gross Profit | $306M | $400M | XXX | XXX | XXX |
| Gross Margin | 28% | 33% | XXX | XXX | XXX |
| EBITDA | $326M | $406M | XXX | XXX | XXX |
| EBITDA Margin | 30% | 34% | XXX | XXX | XXX |
| Net Profit | $178M | $259M | XXX | XXX | XXX |
| Net Margin | 16% | 22% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Shanghai RAAS's stock price is CNY 7 (or $1).
Shanghai RAAS has current market cap of CNY 46.4B (or $6.4B), and EV of CNY 42.7B (or $5.9B).
See Shanghai RAAS trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.9B | $6.4B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Shanghai RAAS has market cap of $6.4B and EV of $5.9B.
Shanghai RAAS's trades at 4.7x LTM EV/Revenue multiple, and 14.0x LTM EBITDA.
Analysts estimate Shanghai RAAS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Shanghai RAAS and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.9B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 14.5x | XXX | XXX | XXX |
| P/E | 20.5x | XXX | XXX | XXX |
| P/E/Growth | 1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpShanghai RAAS's NTM/LTM revenue growth is 12%
Shanghai RAAS's revenue per employee for the last fiscal year averaged $4.0M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Shanghai RAAS's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Shanghai RAAS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Shanghai RAAS and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 46% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $4.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 11% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai RAAS acquired XXX companies to date.
Last acquisition by Shanghai RAAS was XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai RAAS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Shanghai RAAS founded? | Shanghai RAAS was founded in 1988. |
| Where is Shanghai RAAS headquartered? | Shanghai RAAS is headquartered in China. |
| How many employees does Shanghai RAAS have? | As of today, Shanghai RAAS has 272 employees. |
| Is Shanghai RAAS publicy listed? | Yes, Shanghai RAAS is a public company listed on SHE. |
| What is the stock symbol of Shanghai RAAS? | Shanghai RAAS trades under 002252 ticker. |
| When did Shanghai RAAS go public? | Shanghai RAAS went public in 2008. |
| Who are competitors of Shanghai RAAS? | Similar companies to Shanghai RAAS include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Shanghai RAAS? | Shanghai RAAS's current market cap is $6.4B |
| What is the current revenue of Shanghai RAAS? | Shanghai RAAS's last 12-month revenue is $1.2B. |
| What is the current EBITDA of Shanghai RAAS? | Shanghai RAAS's last 12-month EBITDA is $421M. |
| What is the current EV/Revenue multiple of Shanghai RAAS? | Current revenue multiple of Shanghai RAAS is 4.7x. |
| What is the current EV/EBITDA multiple of Shanghai RAAS? | Current EBITDA multiple of Shanghai RAAS is 14.0x. |
| What is the current revenue growth of Shanghai RAAS? | Shanghai RAAS revenue growth between 2023 and 2024 was 10%. |
| Is Shanghai RAAS profitable? | Yes, Shanghai RAAS is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
